
SELFA is a medical device company based on a semiconductor biosensor with extraordinary sensitivity, scalable multiplexing, simultaneous protein and nucleic acid quantitation. SELFA’s technology has broad applicability across diagnostic, point of care (POC), and research tools. This market requires no regulatory clearance, is “clustered” i.e. the opportunities are in relatively few large cities with industrial research and academic organizations, and an easier buy decision. The initial product in development is a low cost, table-top system that uses single-use cartridges with customizable multiplexed biosensors.
Graduated in 2019
Graduated in 2019
Portfolio Companies
- Appia Bio
- Carbonics
- CarbonBuilt
- Dalton Bioanalytics
- EarlyDx
- Electronucleics
- EP Dynamics
- Forcyte Biotechnologies
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoElectronic Imaging
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Qwixel Therapeutics
- Restore Technologies
- Scarless Laboratories
- TrueCath
- Vault Pharma
- ViBo Health
- Westwood Bioscience
- Zenomics